On July 9^th, at the "High-Level Meeting on Thailand's 2026 HPV Vaccination Program" hosted byThaiDepartment of Juvenile Observation&Protection (DJOP), Thai Ministry of Justice and the Thai Gynecologic Cancer Society (TGCS), INNOVAX participated as a key partner and, join hands with Global Biotech Products (GBP)in this program as a CSR program, announced a donation of special funding and bivalent HPV vaccine—Cecolin^®, to support cervical cancer prevention efforts for Thai youth.

The meeting brought together leading experts in Thailand's cervical cancer prevention field, including:

● Prof. Dr. Suwanit Therasakvichaya (Vice President, Thai Gynecologic Cancer Society)

● Flight Lieutenant. Adjunct Assist. Prof. Dr. Tanomsiri Satitit (Social Activities Committee)

● Pol. Lt. Col. Dr. Sirisupa Laohapakorn (Fundraising Subcommittee)

INNOVAX's representative held in-depth discussions with Ms. Preeda Wisaroj (Deputy Director-General, Dept. of Juvenile Observation & Protection) and government officials on:

● Education programs on STDs & cervical cancer prevention

● Nationwide HPV vaccination for youth in detention facilities

● Promoting IPVS-TGCS RUN 2025* - "Run with Heart: Stop Cervical Cancer" (Oct 26, 2025 @ Benjakitti Park)

The Head of Public Relations at INNOVAX stated that we are deeply honored to participate in this Thailand's 2026 HPV Vaccination Program discussion meeting and to collaborate with our strategic Thai partner GBP in advancing the nation's public health strategy for cervical cancer elimination through our bivalent HPV vaccine-Cecolin^® donations and budget support.

The donation will prioritize on:

● Collaboration withThaiDepartment of Juvenile Observation&Protection (DJOP), to provideeducation on cervical cancer and prevention by providing HPV vaccination administration for the children in 32 juvenile training and rehabilitation centers across Thailand.

● Public Awareness Campaign in Thailand: other relevant activities to build knowledge and expand awareness of cervical cancer and pre-invasive cancer to the public via CPG, booklets, public media, and etc.

About INNOVAX's Global Health Initiative

Cecolin^® (bivalent HPV vaccine), since its launch in China in 2019, has demonstrated 100% protection efficacy through a decade of real world follow-up studies. As of July 2025, the vaccine has been approved for market authorization in 23 countries and included in 8 national immunization programs (EPI), with approaching 70 million doses administered globally.

Reported adverse events following immunization (AEFI) have been predominantly mild reactions, confirming its excellent safety profile with no new safety concerns identified.

Cecolin^® 9 (9-valent HPV vaccine), launch in China in 2025, now presents 5 years of consistent observational data and demonstrates non-inferiority in immunogenicity and safety profiles in head-to-head clinical trials versus the approved reference 9-valent HPV vaccine.

Innovax's Cecolin^® Series, is the first HPV vaccine brand in developing country originated from China. To help countries reduce reliance on imported vaccines, Innovax is continuously committed to promoting localized vaccine production through technology transfer. With the support of Thailand's National Vaccine Institute (NVI), we are collaborating with GBP on a 9-valent HPV vaccine technology transfer project, enabling Thailand to establish domestic production capacity and achieve self-sufficiency in vaccine supply.

This is more than a technical partnership—it's a critical step toward global health equity. Only by empowering nations with production sovereignty can we achieve sustainable protection.

As an active implementer to global cervical cancer prevention, INNOVAX is taking concrete actions to advance WHO's 2030 public health goal of eliminating cervical cancer worldwide.